Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: Results of a population-based study

European Journal of Haematology

Volumn 92, Issue 5, 2014, Pages 398-406

  Blommestein, Hedwig M ^a   Issa, Djamila E ^b   Pompen, Marjolein ^c,d   Hoor, Gerhard Ten ^c   Hogendoorn, Mels ^e   Joosten, Peter ^e   Zweegman, Sonja ^b   Huijgens, Peter C ^b   Uyl de Groot, Carin A ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Roche Pharmaceuticals   (Netherlands)

^d BRISTOL MYERS SQUIBB   (United States)

^e MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

Cost effectiveness; Drug policy regulations; Follicular lymphoma; Healthcare decision making; Non Hodgkin lymphoma; Population based; Real world data; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

ADULT; AGED; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; FEMALE; HUMAN; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NETHERLANDS; PATHOLOGY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; REGISTER; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MARKOV CHAINS; MIDDLE AGED; NETHERLANDS; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; REGISTRIES;

EID: 84898789001     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12264     Document Type: Article

References (23)

1. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-52.
2. Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006;24:1582-9.
3. Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford university experience. Blood 2013;122:981-7.
4. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008;112:4824-31.
5. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an east German study group hematology and oncology study. J Clin Oncol 2007;25:1986-92.
6. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group. Blood 2005;106:3725-32.
7. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23.
8. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42-51.
9. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-301.
10. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853-8.
11. Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health 2007;10:326-35 [cited 3/12/2012].
12. Franken MG, van Gils CW, Gaultney JG, et al. Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in the Netherlands. Eur J Cancer 2013;49:8-16.
13. Huijgens PC, Posthuma EFM, Coebergh JWW, van de Poll-Franse LV, Uyl-de Groot CA, Sonneveld P. A 'population based registry' for hemato-oncology. Nederlands Tijdschrift voor Hematologie 2010;7:321-5.
14. Hoogendoorn M, Joosten P, Storm H, Kibbelaar RE. HemoBase: an intelligent electronic patient file as aid for hemato-onocology care. Nederlands Tijdschrift voor Hematologie 2009;6:104-9.
15. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55 [cited 8/1/2013].
16. Tan S, Bouwmans C, Hakkaart-van Roijen L. Handleiding voor kostenonderzoek: Methoden en referentieprijzen voor economische evaluaties in de gezondheidszorg. Diemen: College voor Zorgverzekeringen, 2010.
17. Wild D, Walker M, Pettengell R, Lewis G. Utility elicitation in patients with follicular lymphoma. [abstract no. PCN62]. Value Health 2006;9:A294.
18. Bouwmans C, Janssen J, Huijgens P, Uyl-de Groot C. Costs of haematological adverse events in chronic myeloid leukaemia patients: a retrospective cost analysis of the treatment of anaemia, neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia. J Med Econ 2009;12:164-9.
19. Delwel GO. Guidance for Outcomes Research for the Assessment of the Costeffectiveness of In-Patient Medicines. Diemen, The Netherlands: Health Care Insurance Board; 2008. Report No.: 270: 28113706.
20. Deconinck E, Miadi-Fargier H, Pen CL, Brice P. Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation. Pharmacoeconomics 2010;28:35-46.
21. Castro Gomez AJ, Lopez-Guillermo A, Rueda Dominguez A, Salar A, Varela Moreno C, Rubio-Terres C. Cost-effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line. Rev Esp Salud Publica 2012;86:163-76.
22. Demousis F, Athanasiadis A. Cost-effectiveness analysis of maintenance treatment with rituximab (MabThera) for non-Hodgkins lymphoma patients in Greece, a local adaptation. Value Health 2012;15:A421 (PCN 69).
23. Kasteng F, Erlanson M, Hagberg H, Kimby E, Relander T, Lundkvist J. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol 2008;47:1029-36.